ImmunoPrecise Antibodies (NASDAQ:IPA - Get Free Report) is expected to be releasing its Q4 2025 earnings data before the market opens on Tuesday, July 29th. Analysts expect ImmunoPrecise Antibodies to post earnings of ($0.02) per share and revenue of $7.89 million for the quarter.
ImmunoPrecise Antibodies Trading Up 23.1%
Shares of NASDAQ:IPA traded up $0.42 during midday trading on Thursday, hitting $2.24. 4,871,021 shares of the stock were exchanged, compared to its average volume of 4,468,110. The stock has a market capitalization of $102.50 million, a price-to-earnings ratio of -1.93 and a beta of 0.44. The company has a debt-to-equity ratio of 0.45, a quick ratio of 2.11 and a current ratio of 2.32. The business's 50-day moving average price is $1.03 and its 200 day moving average price is $0.65. ImmunoPrecise Antibodies has a 12 month low of $0.27 and a 12 month high of $2.33.
Wall Street Analyst Weigh In
IPA has been the topic of several analyst reports. Benchmark reiterated a "speculative buy" rating and issued a $3.00 target price on shares of ImmunoPrecise Antibodies in a report on Tuesday, April 1st. HC Wainwright reiterated a "buy" rating and set a $5.00 price objective on shares of ImmunoPrecise Antibodies in a research report on Friday, April 11th. Finally, Wall Street Zen upgraded shares of ImmunoPrecise Antibodies to a "sell" rating in a research report on Saturday, May 24th.
View Our Latest Analysis on IPA
ImmunoPrecise Antibodies Company Profile
(
Get Free Report)
ImmunoPrecise Antibodies Ltd., together with its subsidiaries, operates as a biotherapeutic research and technology company in Canada and internationally. It provides NonaVac DNA for complex protein classes, including GPCRs and ion channels; and Rapid Prime, a positive monoclonal antibodies for generating anti-idiotypic antibodies, and producing monoclonal antibodies against conformational epitopes.
Featured Stories

Before you consider ImmunoPrecise Antibodies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ImmunoPrecise Antibodies wasn't on the list.
While ImmunoPrecise Antibodies currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.